Field production and functional evaluation of chloroplast‐derived interferon‐α2b
Open Access
- 9 May 2007
- journal article
- Published by Wiley in Plant Biotechnology Journal
- Vol. 5 (4) , 511-525
- https://doi.org/10.1111/j.1467-7652.2007.00258.x
Abstract
Type I interferons (IFNs) inhibit viral replication and cell growth and enhance the immune response, and therefore have many clinical applications. IFN-α2b ranks third in world market use for a biopharmaceutical, behind only insulin and erythropoietin. The average annual cost of IFN-α2b for the treatment of hepatitis C infection is $26 000, and is therefore unavailable to the majority of patients in developing countries. Therefore, we expressed IFN-α2b in tobacco chloroplasts, and transgenic lines were grown in the field after obtaining United States Department of Agriculture Animal and Plant Health Inspection Service (USDA-APHIS) approval. Stable, site-specific integration of transgenes into chloroplast genomes and homoplasmy through several generations were confirmed. IFN-α2b levels reached up to 20% of total soluble protein, or 3 mg per gram of leaf (fresh weight). Transgenic IFN-α2b had similar in vitro biological activity to commercially produced PEG-Intron™ when tested for its ability to protect cells against cytopathic viral replication in the vesicular stomatitis virus cytopathic effect (VSV CPE) assay and to inhibit early-stage human immunodeficiency virus (HIV) infection. The antitumour and immunomodulating properties of IFN-α2b were also seen in vivo. Chloroplast-derived IFN-α2b increased the expression of major histocompatibility complex class I (MHC I) on splenocytes and the total number of natural killer (NK) cells. Finally, IFN-α2b purified from chloroplast transgenic lines (cpIFN-α2b) protected mice from a highly metastatic tumour line. This demonstration of high levels of expression of IFN-α2b, transgene containment and biological activity akin to that of commercial preparations of IFN-α2b facilitated the first field production of a plant-derived human blood protein, a critical step towards human clinical trials and commercialization.Keywords
This publication has 57 references indexed in Scilit:
- Expression of cholera toxin B–proinsulin fusion protein in lettuce and tobacco chloroplasts – oral administration protects against development of insulitis in non‐obese diabetic micePlant Biotechnology Journal, 2007
- Stable expression of Gal/GalNAc lectin of Entamoeba histolytica in transgenic chloroplasts and immunogenicity in mice towards vaccine development for amoebiasisPlant Biotechnology Journal, 2007
- Receptor‐mediated oral delivery of a bioencapsulated green fluorescent protein expressed in transgenic chloroplasts into the mouse circulatory systemThe FASEB Journal, 2006
- Engineering Cytoplasmic Male Sterility via the Chloroplast Genome by Expression of β-KetothiolasePlant Physiology, 2005
- A chloroplast transgenic approach to hyper‐express and purify Human Serum Albumin, a protein highly susceptible to proteolytic degradationPlant Biotechnology Journal, 2003
- Molecular strategies for gene containment in transgenic cropsNature Biotechnology, 2002
- Expression of an Antimicrobial Peptide via the Chloroplast Genome to Control Phytopathogenic Bacteria and FungiPlant Physiology, 2001
- Expression of the native cholera toxin B subunit gene and assembly as functional oligomers in transgenic tobacco chloroplasts11Edited by N.-H. ChuaJournal of Molecular Biology, 2001
- INTERFERONS AND THEIR ACTIONSAnnual Review of Biochemistry, 1987
- Structural relationship of human interferon alpha genes and pseudogenesJournal of Molecular Biology, 1985